<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600235</url>
  </required_header>
  <id_info>
    <org_study_id>2012-01-023</org_study_id>
    <nct_id>NCT01600235</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Therapeutic INduced HYPERTENSION in Acute Non-cardioembolic Ischemic Stroke (SETIN-HYPERTENSION)</brief_title>
  <official_title>Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the induced hypertension
      using phenylephrine in patients with noncardioembolic ischemic stroke.

      The investigators hypothesized that phenylephrine induced-hypertension can result in good
      clinical response without serious complications in patients with noncardioembolic ischemic
      stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See below
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome</measure>
    <time_frame>Day 0 and Day 7</time_frame>
    <description>2 points improvement in NIH stroke scale (NIHSS) between days 0 and 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy outcome</measure>
    <time_frame>Day 90 for 1, 2 and Day 7 for 3</time_frame>
    <description>modified Rankin scale (mRS)≤ 2 at day 90
modified Bathel index (mBI)≥ 90 at day 90
Infarct growth or new ischemic lesion on follow-up MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major safety outcome</measure>
    <time_frame>From date of randomization until the date of first documented progression by intracranial hemorrhage or cerebral edema, date of myocardial infarction, or date of death from any cause, whichever came first, assessed up to 3 months</time_frame>
    <description>Symptom aggravation by intracranial hemorrhage or cerebral edema (Clinical deterioration causing an increase in the NIHSS score of more than or equal to 4 points and if the hemorrhage or edema was liley to be the cause of the clinical deterioration)
Myocardial infarction
death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor safety outcome</measure>
    <time_frame>From date of randomization until the date of first documented intracranial hemorrhage on follow-up MRI, or date of first documented side effects, whichever came first, assessed up to 3 months</time_frame>
    <description>Intracranial hemorrhage on follow-up MRI
Side effects including headache, arrhythmia, chest pain, dysuria, or gastrointestinal hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Progressing Stroke</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine induced-hypertension arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg</description>
    <arm_group_label>Phenylephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute ischemic stroke confirmed by diffusion-weighted imaging (DWI)
             performed within 24 hours of symptom onset or symptom worsening(defined by a 2-point
             or more increase in NIH stroke scale (NIHSS)score including one or more increase in
             the motor score of affected upper and lower limbs in NIHSS during hospitalization or
             clear history of symptom worsening judged by investigator before hospitalization)
             confirmed by DWI performed within 24 hours of aggravation.

          -  Baseline NIHSS score 4-18 points

          -  Alert mental status

          -  Newly developed paresis, aphasia, or neglect

        Exclusion Criteria:

          -  Patients underwent recanalization therapy

          -  Systolic blood pressure &gt;170 mmHg at baseline

          -  Patients with history or at risk of hemorrhagic stroke

          -  History of significant arrhythmia (e.g. atrial fibrillation)

          -  Unable to perform MRI scans or undergo MRI scans &gt; 24 hours of symptom onset or
             progression

          -  Large cortical infarction on DWI (more than 1/2 of middle cerebral artery territory)

          -  3 or more cortical microbleeds on gradient-echo MRI

          -  Coronary artery disease, congestive heart failure, or hypertrophic cardiomyopathy

          -  Anticoagulation therapy (phenylephrine group only)

          -  Patients with high-risk cardioembolic sources

          -  Cervical or cerebral artery dissection or unruptured aortic/cerebral arterial aneurysm

          -  Decreased consciousness

          -  Pregnant or Lactating patient

          -  Seizure at stroke onset

          -  Life expectancy &lt; 6 months

          -  Pre-stroke modified Rankin scale (mRS) &gt;= 2

          -  Patients without informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oh Young Bang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oh Young Bang, MD</last_name>
    <phone>82-10-3410-3599</phone>
    <email>nmboy@unitel.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mi Hyun Seo, RN</last_name>
    <phone>82-10-3410-0934</phone>
    <email>mh84.seo@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Jae Kim, MD</last_name>
      <phone>82234101895</phone>
      <email>sukjae.kim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oh Young Bang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwang Ho Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin-Sang Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gyeong-Moon Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Ji Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suk Jae Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sookyung Ryoo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Oh Young Bang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke, ischemic</keyword>
  <keyword>Progression</keyword>
  <keyword>Induced-hypertension</keyword>
  <keyword>Phenylephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

